T-Cell Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

T-cell lymphoma treatment a first for Nevada - Las Vegas Review-Journal



Las Vegas Review-Journal
 
T-cell lymphoma treatment a first for Nevada 
Las Vegas Review-Journal
Larry Loman receives a photopheresis treatment at United Blood Services on Wednesday, Nov. 1, 2017, in Las Vegas. Loman is the first patient in Vegas to receive photopheresis treatment for cutaneous T-cell lymphoma. Bizuayehu Tesfaye/Las Vegas ...

 


Peripheral T-Cell Lymphoma (PTCL)- Epidemiology Forecast to 2025 - PR Newswire (press release)



Peripheral T-Cell Lymphoma (PTCL)- Epidemiology Forecast to 2025 
PR Newswire (press release)
NEW YORK, Nov. 17, 2017 /PRNewswire/ -- DelveInsight's "Peripheral T Cell Lymphoma (PTCL) -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Peripheral T Cell Lymphoma (PTCL) in seven major markets (US, France, ...

and more » 


This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected - Labiotech.eu (blog)



Labiotech.eu (blog)
 
This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected 
Labiotech.eu (blog)
Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form of cancer that affects the cells responsible for protecting our body ...
New targeting approach to treat T-cell lymphomas published EPM Magazine
Unique approach to treatment of rare and aggressive blood cancers Medical Xpress

all 3 news articles » 


FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma - Medscape



Medscape
 
FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma 
Medscape
The US Food and Drug Administration (FDA) today approved brentuximab vedotin (Adcetris, Seattle Genetics and Takeda) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received prior systemic therapy. Specifically, it was ...
(Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing ... Business Wire (press release)
FDA approves drug developed in Bothell to treat disfiguring blood cancer The Daily Herald
FDA approves Adcetris for primary cutaneous anaplastic large cell lymphoma Healio
OncLive  -Curetoday.com  -Specialty Pharmacy Times 
all 13 news articles » 


Cutaneous T-Cell Lymphoma(CTCL)- Epidemiology Forecast to 2025 - PR Newswire (press release)



Cutaneous T-Cell Lymphoma(CTCL)- Epidemiology Forecast to 2025 
PR Newswire (press release)
NEW YORK, Nov. 17, 2017 /PRNewswire/ -- DelveInsight's "Cutaneous T Cell Lymphoma(CTCL) -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Cutaneous T Cell Lymphoma(CTCL) in seven major markets (US, France, ...

and more » 


EFS at 24 Months Predicts Mortality in Peripheral T-Cell Lymphoma - Cancer Network



EFS at 24 Months Predicts Mortality in Peripheral T-Cell Lymphoma 
Cancer Network
Previous research showed that EFS can be useful in stratifying patients with other lymphomas including diffuse large B-cell lymphoma and follicular lymphoma treated with immunochemotherapy, and researchers led by Andrew L. Feldman, MD, of the Mayo ...

 


Cutaneous T-Cell Lymphoma(CTCL) - Market Insights ... - PR Newswire (press release)



Cutaneous T-Cell Lymphoma(CTCL) - Market Insights ... 
PR Newswire (press release)
DelveInsight's "Cutaneous T Cell Lymphoma(CTCL) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and ...

and more » 


Cutaneous T-cell Lymphoma Therapy Adcetris Approved by FDA - Lymphoma News Today



Lymphoma News Today
 
Cutaneous T-cell Lymphoma Therapy Adcetris Approved by FDA 
Lymphoma News Today
The FDA has approved Adcetris for the treatment of adults with primary cutaneous anaplastic large cell lymphoma and CD30-expressing mycosis fungoides.
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion ... Nasdaq
Seattle Genetics wins new OK for Adcetris | BioPharma Dive BioPharma Dive

all 3 news articles » 


12-year-old Blanchard boy recovering from Lymphoma diagnosis - kfor.com



kfor.com
 
12-year-old Blanchard boy recovering from Lymphoma diagnosis 
kfor.com
"He was eventually diagnosed with a type of cancer called Lymphoma, and specifically a T-Cell lymphoblastic lymphoma," explained Pediatric oncologist Dr. Joel Thompson. It is a very rare subtype of non-Hodgkin's lymphoma that tends to develop in ...

 


Dr. Brammer on Updates in the Treatment Landscape for T-Cell ... - OncLive



OncLive
 
Dr. Brammer on Updates in the Treatment Landscape for T-Cell ... 
OncLive
Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment ...

and more »